$AMED
AMEDISYS INC

2022 Q3 Form 10-Q Financial Statement

#000089626222000055 Filed on July 28, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2021 Q4
Revenue $558.0M $557.9M $559.3M
YoY Change 0.81% -1.11% 1.56%
Cost Of Revenue $322.2M $316.2M $299.7M
YoY Change 3.83% 2.43% -2.3%
Gross Profit $239.8M $244.7M $259.7M
YoY Change -2.81% -5.87% 6.42%
Gross Profit Margin 42.97% 43.86% 46.42%
Selling, General & Admin $188.3M $187.8M $184.9M
YoY Change 5.26% 7.19% 5.27%
% of Gross Profit 78.55% 76.76% 71.19%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $5.477M $6.220M $9.138M
YoY Change -26.85% -6.83% 3.84%
% of Gross Profit 2.28% 2.54% 3.52%
Operating Expenses $193.8M $194.0M $194.0M
YoY Change 3.97% 6.65% 5.14%
Operating Profit $38.90M $47.60M $65.67M
YoY Change -31.51% -39.05% 10.37%
Interest Expense $4.963M $8.311M -$1.774M
YoY Change 81.79% 330.18% 121.75%
% of Operating Profit 12.76% 17.46% -2.7%
Other Income/Expense, Net -$4.111M -$7.285M $492.0K
YoY Change 416.46% -123.48% -18.0%
Pretax Income $34.82M $40.36M $46.88M
YoY Change -37.79% -63.03% -24.38%
Income Tax $9.417M $11.32M $12.87M
% Of Pretax Income 27.04% 28.05% 27.46%
Net Earnings $25.64M $29.58M $34.05M
YoY Change -43.03% -63.09% -24.51%
Net Earnings / Revenue 4.6% 5.3% 6.09%
Basic Earnings Per Share $0.79 $0.91
Diluted Earnings Per Share $0.79 $0.91 $1.037M
COMMON SHARES
Basic Shares Outstanding 32.44M shares 32.52M shares 32.60M shares
Diluted Shares Outstanding 32.62M shares 32.68M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.96M $26.57M $42.69M
YoY Change -85.57% -71.01% -47.81%
Cash & Equivalents $18.00M $26.60M $42.70M
Short-Term Investments
Other Short-Term Assets $37.84M $25.49M $25.60M
YoY Change 169.82% 213.8% 92.47%
Inventory
Prepaid Expenses $17.01M $15.20M $10.36M
Receivables $302.5M $305.4M $275.0M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $388.8M $394.9M $356.7M
YoY Change -10.19% 1.0% -1.46%
LONG-TERM ASSETS
Property, Plant & Equipment $17.25M $17.85M $18.44M
YoY Change -15.37% -14.96% -22.22%
Goodwill $1.285B $1.290B $1.196B
YoY Change 8.2% 37.67% 28.24%
Intangibles $103.7M $106.2M $111.2M
YoY Change -12.2% 59.85% 49.85%
Long-Term Investments $61.50M $65.00M $53.10M
YoY Change 27.33% 44.12%
Other Assets $81.12M $84.69M $73.02M
YoY Change 19.11% 32.11% 119.95%
Total Long-Term Assets $1.593B $1.606B $1.500B
YoY Change 5.89% 32.89% 24.48%
TOTAL ASSETS
Total Short-Term Assets $388.8M $394.9M $356.7M
Total Long-Term Assets $1.593B $1.606B $1.500B
Total Assets $1.982B $2.001B $1.857B
YoY Change 2.3% 25.1% 18.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $45.53M $43.51M $38.22M
YoY Change 9.31% 18.66% -10.44%
Accrued Expenses $130.1M $176.2M $150.8M
YoY Change -15.66% 6.07% -9.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $12.60M $12.50M $13.00M
YoY Change -4.55% 22.55% 23.81%
Total Short-Term Liabilities $367.2M $427.4M $374.3M
YoY Change -19.18% -4.86% -17.98%
LONG-TERM LIABILITIES
Long-Term Debt $443.4M $442.4M $432.1M
YoY Change 1.98% 146.6% 111.3%
Other Long-Term Liabilities $13.87M $13.41M $4.979M
YoY Change -56.63% -57.95% -85.18%
Total Long-Term Liabilities $457.3M $455.8M $437.1M
YoY Change -2.04% 115.73% 83.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $367.2M $427.4M $374.3M
Total Long-Term Liabilities $457.3M $455.8M $437.1M
Total Liabilities $912.5M $962.0M $880.6M
YoY Change -7.72% 32.93% 16.42%
SHAREHOLDERS EQUITY
Retained Earnings $726.0M $700.3M $639.1M
YoY Change 19.99% 25.05% 48.62%
Common Stock $750.9M $743.3M $728.1M
YoY Change 4.17% 4.05% 4.27%
Preferred Stock
YoY Change
Treasury Stock (at cost) $461.2M $458.0M $435.9M
YoY Change 9.63% 14.46% 36.6%
Treasury Stock Shares 5.373M shares 5.348M shares 5.165M shares
Shareholders Equity $1.016B $985.6M $931.4M
YoY Change
Total Liabilities & Shareholders Equity $1.982B $2.001B $1.857B
YoY Change 2.3% 25.1% 18.49%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2021 Q4
OPERATING ACTIVITIES
Net Income $25.64M $29.58M $34.05M
YoY Change -43.03% -63.09% -24.51%
Depreciation, Depletion And Amortization $5.477M $6.220M $9.138M
YoY Change -26.85% -6.83% 3.84%
Cash From Operating Activities -$13.63M $57.41M $5.166M
YoY Change -122.07% -15.53% -92.17%
INVESTING ACTIVITIES
Capital Expenditures -$1.845M -$2.203M -$1.387M
YoY Change -22.84% 64.04% -39.7%
Acquisitions
YoY Change
Other Investing Activities $812.0K -$73.31M -$10.28M
YoY Change -100.31% 2790.58% -1568.57%
Cash From Investing Activities -$1.033M -$75.51M -$11.67M
YoY Change -99.61% 1898.09% 629.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.641M -4.046M -75.94M
YoY Change -101.11% -91.87% -21.31%
NET CHANGE
Cash From Operating Activities -13.63M 57.41M 5.166M
Cash From Investing Activities -1.033M -75.51M -11.67M
Cash From Financing Activities -2.641M -4.046M -75.94M
Net Change In Cash -17.30M -22.15M -82.44M
YoY Change -148.66% -253.9% 156.82%
FREE CASH FLOW
Cash From Operating Activities -$13.63M $57.41M $5.166M
Capital Expenditures -$1.845M -$2.203M -$1.387M
Free Cash Flow -$11.78M $59.61M $6.553M
YoY Change -118.37% -13.98% -90.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
AMEDISYS INC
dei Entity Central Index Key
EntityCentralIndexKey
0000896262
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
510249000 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
490634000 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-24260
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3131700
dei Entity Address Address Line1
EntityAddressAddressLine1
3854 American Way
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite A
dei Entity Address City Or Town
EntityAddressCityOrTown
Baton Rouge
dei Entity Address State Or Province
EntityAddressStateOrProvince
LA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
70816
dei City Area Code
CityAreaCode
225
dei Local Phone Number
LocalPhoneNumber
292-2031
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
AMED
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32443341 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26566000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42694000 usd
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
22198000 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
3075000 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
305413000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
274961000 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15199000 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10356000 usd
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
25493000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
25598000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
394869000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
356684000 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
100265000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
96937000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17847000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18435000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
107723000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
101257000 usd
CY2022Q2 us-gaap Goodwill
Goodwill
1289672000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
1196090000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9109000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19900000 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
106189000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
111190000 usd
CY2022Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
289000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
84686000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
73023000 usd
CY2022Q2 us-gaap Assets
Assets
2000986000 usd
CY2021Q4 us-gaap Assets
Assets
1856968000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
43509000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
38217000 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
161068000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
141001000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
176239000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
150836000 usd
CY2022Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
12521000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
12995000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
34035000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
31233000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
427372000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
374282000 usd
CY2022Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
442413000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
432075000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
72619000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
69309000 usd
CY2022Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
6179000 usd
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0 usd
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
13408000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4979000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
961991000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
880645000 usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2021Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37780242 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37674868 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32432527 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32509969 shares
CY2022Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
38000 usd
CY2021Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
38000 usd
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
743276000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
728118000 usd
CY2022Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
5347715 shares
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
5164899 shares
CY2022Q2 us-gaap Treasury Stock Value
TreasuryStockValue
457981000 usd
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
435868000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
700313000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
639063000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
985646000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
931351000 usd
CY2022Q2 us-gaap Minority Interest
MinorityInterest
53349000 usd
CY2021Q4 us-gaap Minority Interest
MinorityInterest
44972000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1038995000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
976323000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2000986000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1856968000 usd
CY2022Q2 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
557890000 usd
CY2021Q2 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
564166000 usd
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1103147000 usd
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1101310000 usd
CY2022Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0 usd
CY2021Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
4603000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
13304000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
316211000 usd
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
308691000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
621031000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
605894000 usd
CY2022Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
127758000 usd
CY2021Q2 us-gaap Labor And Related Expense
LaborAndRelatedExpense
114335000 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
251238000 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
230160000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
5148000 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
6156000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12495000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
13463000 usd
CY2022Q2 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
54912000 usd
CY2021Q2 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
54731000 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
108552000 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
103837000 usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
6220000 usd
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
6721000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
14228000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
14276000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
510249000 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
490634000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1007544000 usd
us-gaap Costs And Expenses
CostsAndExpenses
967630000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
47641000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
78135000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
95603000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
146984000 usd
CY2022Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
36000 usd
CY2021Q2 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
25000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
49000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
49000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
8311000 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
1932000 usd
us-gaap Interest Expense
InterestExpense
11484000 usd
us-gaap Interest Expense
InterestExpense
4004000 usd
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
659000 usd
CY2021Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1370000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-744000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2488000 usd
CY2022Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
0 usd
CY2021Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
31092000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
0 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
31092000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
331000 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
475000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
664000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
763000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7285000 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
31030000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11515000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
30388000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
40356000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
109165000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
84088000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
177372000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11319000 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28546000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23338000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
46461000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
29037000 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
80619000 usd
us-gaap Profit Loss
ProfitLoss
60750000 usd
us-gaap Profit Loss
ProfitLoss
130911000 usd
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-542000 usd
CY2021Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
470000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-500000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
892000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
29579000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
80149000 usd
us-gaap Net Income Loss
NetIncomeLoss
61250000 usd
us-gaap Net Income Loss
NetIncomeLoss
130019000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.91
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.98
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32522000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32588000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32538000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32684000 shares
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.91
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.87
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.93
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32681000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32981000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32722000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33085000 shares
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1020652000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
906000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
686000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5148000 usd
CY2022Q2 amed Surrendered Shares
SurrenderedShares
80000 usd
CY2022Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
17351000 usd
CY2022Q2 amed Contributions Attributable To Noncontrolling Interest
ContributionsAttributableToNoncontrollingInterest
300000 usd
CY2022Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
303000 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
29037000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1038995000 usd
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
789574000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
913000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
259000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6156000 usd
CY2021Q2 amed Surrendered Shares
SurrenderedShares
170000 usd
CY2021Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1188000 usd
CY2021Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
276000 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
80619000 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
875887000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
976323000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1891000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
772000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12495000 usd
amed Surrendered Shares
SurrenderedShares
4762000 usd
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
17351000 usd
amed Contributions Attributable To Noncontrolling Interest
ContributionsAttributableToNoncontrollingInterest
9852000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
975000 usd
us-gaap Profit Loss
ProfitLoss
60750000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1038995000 usd
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
810741000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1961000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
623000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13463000 usd
amed Surrendered Shares
SurrenderedShares
6944000 usd
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
74074000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
794000 usd
us-gaap Profit Loss
ProfitLoss
130911000 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
875887000 usd
us-gaap Profit Loss
ProfitLoss
60750000 usd
us-gaap Profit Loss
ProfitLoss
130911000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14228000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14276000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12495000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
13463000 usd
amed Amortizationand Impairmentof Operating Lease Right Of Use Asset
AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
22463000 usd
amed Amortizationand Impairmentof Operating Lease Right Of Use Asset
AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
19702000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-531000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-8000 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
31092000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
6003000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
22716000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-744000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2488000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
495000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
432000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
2428000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
2683000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
21344000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
22787000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4468000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3560000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-220000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
52000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4498000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6530000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
29529000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1627000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-223000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1736000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-20657000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-17955000 usd
amed Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1662000 usd
amed Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1524000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
106030000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
121960000 usd
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
28000 usd
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
25000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
37000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
42000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2782000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2943000 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
559000 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
0 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
15000000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
73311000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
2503000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-91587000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5379000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
772000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
623000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1891000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1961000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4762000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
6944000 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
952000 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0 usd
amed Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
975000 usd
amed Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
794000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
298500000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
389200000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
283500000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
410200000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
6975000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5392000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
17351000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
74074000 usd
amed Funds Received From Provider Relief Fund Advance
FundsReceivedFromProviderReliefFundAdvance
0 usd
amed Funds Received From Provider Relief Fund Advance
FundsReceivedFromProviderReliefFundAdvance
-1672000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-11448000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-107292000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2995000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
9289000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45769000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83357000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48764000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92646000 usd
us-gaap Interest Paid Net
InterestPaidNet
4489000 usd
us-gaap Interest Paid Net
InterestPaidNet
1914000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
22977000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
8667000 usd
amed Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
22319000 usd
amed Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
19479000 usd
amed Cash Paid For Finance Lease Liabilities
CashPaidForFinanceLeaseLiabilities
735000 usd
amed Cash Paid For Finance Lease Liabilities
CashPaidForFinanceLeaseLiabilities
1017000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
26590000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
20689000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1316000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
527000 usd
amed Lessee Operatinglease Reductionsto Ro Uassetsresultingfromreductionstoleaseobligations
LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
2763000 usd
amed Lessee Operatinglease Reductionsto Ro Uassetsresultingfromreductionstoleaseobligations
LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
904000 usd
amed Non Cash Accrued Contingent Consideration
NonCashAccruedContingentConsideration
19195000 usd
amed Non Cash Accrued Contingent Consideration
NonCashAccruedContingentConsideration
0 usd
amed Non Cash Noncontrolling Interest Contribution
NonCashNoncontrollingInterestContribution
8900000 usd
amed Non Cash Noncontrolling Interest Contribution
NonCashNoncontrollingInterestContribution
0 usd
CY2022Q2 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
38 state
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div>
CY2022Q2 amed Minimum Percent Ownership For Controlling Interest Percent
MinimumPercentOwnershipForControllingInterestPercent
0.50
CY2022Q2 amed Maximum Percent Ownership For Equity Method Percent
MaximumPercentOwnershipForEquityMethodPercent
0.50
CY2022Q2 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
45000000 usd
CY2021Q4 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
48100000 usd
CY2022Q2 amed Maximum Percent Ownership For Cost Method Percent
MaximumPercentOwnershipForCostMethodPercent
0.20
CY2022Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
15000000 usd
CY2022Q2 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
20000000 usd
CY2021Q4 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
5000000 usd
amed Historical Collection Rate From Medicare
HistoricalCollectionRateFromMedicare
0.99
CY2022Q2 amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
CY2021Q2 amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Episode Payment Rate Duration
NetServiceRevenueEpisodePaymentRateDuration
P60D
amed Net Service Revenue Episode Payment Rate Duration
NetServiceRevenueEpisodePaymentRateDuration
P60D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Percentage Of Total Reimbursement Of Outlier Payment
PercentageOfTotalReimbursementOfOutlierPayment
0.10
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
CY2021Q2 amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
CY2022Q2 amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26600000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42700000 usd
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
22200000 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
3100000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48800000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45800000 usd
amed Percentage Of Patient Receivables Outstanding
PercentageOfPatientReceivablesOutstanding
0.10
CY2022Q2 amed Accounts Receivable Portion Derived From Medicare
AccountsReceivablePortionDerivedFromMedicare
0.68
CY2021Q4 amed Accounts Receivable Portion Derived From Medicare
AccountsReceivablePortionDerivedFromMedicare
0.68
amed Historical Collection Rate From Medicare
HistoricalCollectionRateFromMedicare
0.99
CY2022Q2 amed Debt Instrument Carrying Amount Excluding Finance Leases
DebtInstrumentCarryingAmountExcludingFinanceLeases
456800000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32522000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32588000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32538000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32684000 shares
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
46000 shares
CY2021Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
139000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
56000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
145000 shares
CY2022Q2 amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
113000 shares
CY2021Q2 amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
254000 shares
amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
128000 shares
amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
256000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32681000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32981000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32722000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33085000 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
283000 shares
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
71000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
250000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
58000 shares
CY2020Q1 amed Funding For Healthcare Providers Including Hospitals
FundingForHealthcareProvidersIncludingHospitals
175000000000 usd
CY2020Q1 amed Funding Immediately Distributed To Healthcare Providers Based On Their2019 Medicare Fee For Service Reimbursements
FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
30000000000 usd
CY2020Q2 amed Funding Received From Cares Act
FundingReceivedFromCARESAct
100000000 usd
CY2020Q1 amed Funding Immediately Distributed To Healthcare Providers Based On Their2019 Medicare Fee For Service Reimbursements
FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
30000000000 usd
amed Cares Act Provider Relief Funds Utilized
CARESActProviderReliefFundsUtilized
46600000 usd
CY2021Q4 amed Cares Act Interest Repaid To Government
CARESActInterestRepaidToGovernment
200000 usd
CY2021Q4 amed Estimated Cares Act Provider Relief Fund Amounts Repaid
EstimatedCARESActProviderReliefFundAmountsRepaid
58300000 usd
amed Cares Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures
CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures
1300000 usd
CY2021Q4 amed Estimated Cares Act Provider Relief Fund Amounts Repaid By Unconsolidated Joint Ventures
EstimatedCARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures
600000 usd
CY2021Q4 amed Total Cares Act Provider Relief Funds Received
TotalCARESActProviderReliefFundsReceived
106800000 usd
CY2022Q2 amed Extension Of Temporary Suspension Of Sequestration Revenue Impact
ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
4000000 usd
amed Extension Of Temporary Suspension Of Sequestration Revenue Impact
ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
13000000 usd
CY2021Q2 amed Extension Of Temporary Suspension Of Sequestration Revenue Impact
ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
10000000 usd
amed Extension Of Temporary Suspension Of Sequestration Revenue Impact
ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
18000000 usd
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
459000000.0 usd
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
449600000 usd
CY2022Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
4100000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segments
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
4500000 usd
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
454900000 usd
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
445100000 usd
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
12500000 usd
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
13000000.0 usd
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
442400000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
432100000 usd
CY2022Q2 amed Total Leverage Ratio
TotalLeverageRatio
1.7
CY2022Q2 amed Consolidated Interest Coverage Ratio
ConsolidatedInterestCoverageRatio
15.4
amed Health Insurance Retention Limit
HealthInsuranceRetentionLimit
1300000 usd
amed Workers Compensation Insurance Retention Limit
WorkersCompensationInsuranceRetentionLimit
2000000 usd
amed Professional Liability Insurance Retention Limit
ProfessionalLiabilityInsuranceRetentionLimit
300000 usd
CY2022Q2 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
557900000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
316200000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
187900000 usd
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
6200000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
47600000 usd
CY2021Q2 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
564200000 usd
CY2021Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
4600000 usd
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
308700000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
175300000 usd
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
6700000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
78100000 usd
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1103100000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
621000000.0 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
372300000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
14200000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1007500000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
95600000 usd
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1101300000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
13300000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
605900000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
347400000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
14300000 usd
us-gaap Costs And Expenses
CostsAndExpenses
967600000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
147000000.0 usd

Files In Submission

Name View Source Status
0000896262-22-000055-index-headers.html Edgar Link pending
0000896262-22-000055-index.html Edgar Link pending
0000896262-22-000055.txt Edgar Link pending
0000896262-22-000055-xbrl.zip Edgar Link pending
amed-20220630.htm Edgar Link pending
amed-20220630.xsd Edgar Link pending
amed-20220630_cal.xml Edgar Link unprocessable
amed-20220630_def.xml Edgar Link unprocessable
amed-20220630_g1.jpg Edgar Link pending
amed-20220630_htm.xml Edgar Link completed
amed-20220630_lab.xml Edgar Link unprocessable
amed-20220630_pre.xml Edgar Link unprocessable
amed-20223006xexx311.htm Edgar Link pending
amed-20223006xexx312.htm Edgar Link pending
amed-20223006xexx321.htm Edgar Link pending
amed-20223006xexx322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending